+

WO2006109979A1 - Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5 - Google Patents

Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5 Download PDF

Info

Publication number
WO2006109979A1
WO2006109979A1 PCT/KR2006/001324 KR2006001324W WO2006109979A1 WO 2006109979 A1 WO2006109979 A1 WO 2006109979A1 KR 2006001324 W KR2006001324 W KR 2006001324W WO 2006109979 A1 WO2006109979 A1 WO 2006109979A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
extract
ginsenoside
cancer
present
Prior art date
Application number
PCT/KR2006/001324
Other languages
English (en)
Other versions
WO2006109979A9 (fr
Inventor
You Sup Chung
Jin Hwa Choi
Original Assignee
Biomedgenomics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedgenomics Co., Ltd. filed Critical Biomedgenomics Co., Ltd.
Priority to CA2604064A priority Critical patent/CA2604064C/fr
Priority to DE112006000924T priority patent/DE112006000924T5/de
Priority to JP2008506371A priority patent/JP5185106B2/ja
Priority to GB0719741A priority patent/GB2441902B/en
Priority to CN2006800117682A priority patent/CN101155521B/zh
Priority claimed from KR1020060032584A external-priority patent/KR100777189B1/ko
Publication of WO2006109979A1 publication Critical patent/WO2006109979A1/fr
Publication of WO2006109979A9 publication Critical patent/WO2006109979A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a method for preparing novel processed ginseng to obtain increased amount of ginsenoside Rg5. More particularly, the present invention relates to a method for preparing processed ginseng product and the extract thereof which contains increased amount of ginsenoside Rg5 by treating ginseng under specific pressure and temperature range.
  • ginseng enforces non-specific resistance to psychological stress and shows maintaining effect on human homeostasis together with other potent pharmacological activities, i.e., alleviation of hypertension, reinforcing activity of insulin, blood glucose lowering activity, stimulating effect on liver RNA synthesis, protein, glucose and lipid metabolism or anticancer activity.
  • Panax ginseng distributed or cultivated in far-eastern Asia region, Panax quinquefolia in America and Canada, Panax notoginseng in China, Panax trifolia in eastern region of north America, Panax japonica in Japan, China and Nepal, Panax pseudoginseng in Nepal, Panax vietnamensis in Vietnam, Panax elegatior, Panax wangianus and Panax bipinratifidus etc.
  • Ginsenosidal saponins isolated from ginseng having dammarane skeleton linked to several saccharides are different from those isolated from the other plants.
  • ginseng contains about 30 kinds of saponin ingredients, especially ginsenoside RbI, Rb2, Rc, Rd, Rg, Re etc as main components.
  • ginsenoside RbI, Rb2, Rc, Rd, Rg, Re etc as main components.
  • Those saponin compounds shows various pharmacological activities and potency according to their chemical structure and ginsenoside Rg5 among them has been high- lightened as a medicine due to its potent immuno- potentiating activity as well as vasodilating activity, anti-cancer activity, neuronal cell protecting activity etc recently.
  • Korean Patent Registration No. 10-0192678 discloses a process for preparing a processed ginseng prepared by subjecting hot temperature treatment containing high contents of ginsenoside Rg5 so as to obtaining processed ginseng having improved potency differing from original form of ginseng.
  • the processing method could not provide the information on the correlation between the content change of ginsenoside Rg5 and the change of temperature and internal pressure and the method requires toxic organic solvent such as butanol.
  • the present invention provides a processing method for preparing pharmacologically potent ginseng product and the extract therefrom which obtain maximized content of ginsenoside Rg5 characterized in treating ginseng with selected ranges of pressure and temperature.
  • the present invention provides a processing method for preparing pharmacologically potent ginseng product consisting of the steps comprising; adding about 1 to 3 times weight of water based on the weight of ginseng to five to seven years old ginseng material, preferably six year old ginseng material; and treating step
  • the final ginseng product of the present invention contains much more amount of ginsenoside Rg5, about two to five times, specifically about 4.4 times than the processed ginseng prepared from the method disclosed in Korean Patent Registration No. 10-0192678.
  • the final ginseng product of the present invention contains much more amount of ginsenoside Rg5, about two to five times, specifically about 3.3 times than the processed ginseng prepared from the method disclosed in Korean Patent Registration No. 10-0192678.
  • the present invention also provides a method for extracting the extract of processed ginseng consisting of the steps comprising: extracting processed ginseng material prepared from the above described step with the mixture of organic solvent, preferably, the mixture of methanol and methylene chloride, more preferably, mixture of methanol and methylene chloride with the mixed ratio ranging from 0.60: 1.40 to 1.20:0.80, more preferably, about l:l(v/v) mixture of methanol and methylene chloride with reflux extraction method in the period ranging from 1 hr to two days, preferably more than 1 hour; filtrating to obtain filtrate, concentrating the filtrate to remove remaining solvent and drying to obtain potent ginseng extract having large amount of ginsenoside Rg5.
  • the "ginseng material” disclosed herein aged six years old is preferably used in the present invention since six years old ginseng showed higher amount of ginsenoside Rg5 than four years old ginseng, which was confirmed by following experiments prosecuted by the present inventors.
  • the "ginseng material” disclosed herein comprise the leaf thereof which has been reported to be useless as well as root part of ginseng in the present invention since it is confirmed that the processed leaf of ginseng of the present invention showed equivalent amount of ginsenoside Rg5 to the root part of ginseng, which was confirmed by following experiments prosecuted by the present inventors.
  • the ginseng thus processed or the extract thereof may be dried by a known manner to obtain a dried processed ginseng, for example, dried at a lower temperature, i.e., below 70°C for the period ranging from about 48 to 60 hrs or freeze-drying method and it may be further processed to be pulverized or powdered into the smaller size, preferably, the size ranging from about 50 to 200 micrometer by the method well- known in the art, if necessary, to prepare commercially available final product such as capsule, tablet etc using by pharmaceutically acceptable carrier or adjuvant.
  • a dried processed ginseng for example, dried at a lower temperature, i.e., below 70°C for the period ranging from about 48 to 60 hrs or freeze-drying method and it may be further processed to be pulverized or powdered into the smaller size, preferably, the size ranging from about 50 to 200 micrometer by the method well- known in the art, if necessary, to prepare commercially available final product such as capsule, tablet etc using by pharmaceutically acceptable carrier
  • the inventive processed ginseng of the present invention contains abundant ginsenoside Rg5 showing potent pharmacological activity such as vasodilating activity, immuno-potentiating activity, anti-cancer activity, neuronal cell-protecting activity etc, anti-cancer activity in particular.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the ginseng extract prepared from the above-described processing method and a pharmaceutically acceptable carrier or adjuvants for the treatment or prevention of cancer disease and the method of the present invention can provide with maximized content of ginsenoside Rg5 by adopting selected ranges of pressure and temperature.
  • cancer comprises various cancers such as stomach cancer, liver cancer, lung cancer, cervical cancer, skin cancer, stomach cancer, or breast cancer, specifically skin cancer.
  • the ginseng extract of the present invention has potent anticancer activity and therefore, the pharmaceutical composition of the present invention thus may be employed to treat or prevent various cancer diseases.
  • the present invention also provides a use of ginseng extract prepared from above- described processing method for manufacture of medicines employed for treating or preventing various cancer such as stomach cancer, liver cancer, lung cancer in men, and cervical cancer, skin cancer, stomach cancer, breast cancer.
  • an method of treating or preventing various cancer such as stomach cancer, liver cancer, lung cancer in men, and cervical cancer, stomach cancer, breast cancer, wherein the method comprises administering a therapeutically effective amount of the ginseng extract prepared from above-described processing method.
  • the inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • compositions of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the compounds of the present invention can be formulated in the form of ointments and creams.
  • compositions containing present composition may be prepared in any form, such as oral dosage form (powder, latinor-pulves, granule, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, solution, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion, injection).
  • oral dosage form poowder, latinor-pulves, granule, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, solution, powder, sachet, granule
  • topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
  • injectable preparation solution, suspension, emulsion, injection.
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.2-200mg/kg, preferably, 2 to 100mg/kg by weight/day of the inventive extract or compounds of the present invention. The dose may be administered in single or divided into several times per day.
  • the complex herbal composition should be present between 0.01 to 80% by weight, preferably 0.5 to 50% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intracerebroventricular injection.
  • composition therein can be used for the prevention or alleviation of various cancer diseases.
  • the amount of above described extract may generally range from about 0.1 to 15 w/w %, preferably 1 to 10 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably 3 to 10 g on the ratio of IOOD of the health beverage composition.
  • the composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes.
  • administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intracerebroventricular injection in any form, such as oral dosage form (powder, latinor-pulves, granule, tablet, capsule, soft capsule, syrup, elixirs pill, solution, powder, sachet or granule).
  • oral dosage form prowder, latinor-pulves, granule, tablet, capsule, soft capsule, syrup, elixirs pill, solution, powder, sachet or granule).
  • the health beverage composition of present invention contains the above described extract as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cyclodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably 5 to 12 g in the ratio of IOOD of present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination.
  • the ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition.
  • Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health care food and the like.
  • the method for preparing processed ginseng according to present invention could provide abundant amount ginsenoside Rg5 showing various pharmacological activities with applying selected specific pressure and temperature into the method and the composition comprising the processed ginseng and the extract thereof can be useful as a medicament or health care food in the prevention or treatment of various diseases, cancer, particularly.
  • Fig. 1 shows the result of LC and Mass spectrum of ginseng extract (Gl-I);
  • Fig. 2 shows the result of LC and Mass spectrum of ginseng extract (Gl-2);
  • Fig. 3 shows the result of LC and Mass spectrum of ginseng extract (Gl-3);
  • Fig. 4 shows the result of LC and Mass spectrum of ginseng extract (Gl-4);
  • Fig. 5 shows the result of LC and Mass spectrum of ginseng extract (Gl-5);
  • Fig. 6 shows the result of LC and Mass spectrum of ginseng extract (Gl-6);
  • Fig. 7 shows the result of LC and Mass spectrum of ginseng extract (Gl-7).
  • FIG. 8 shows the result of LC and Mass spectrum of ginseng extract (G2-1);
  • FIG. 9 shows the result of LC and Mass spectrum of ginseng extract (G2-2);
  • FIG. 10 shows the result of LC and Mass spectrum of ginseng extract (G2-3).
  • FIG. 11 shows the result of LC and Mass spectrum of ginseng extract (G3)
  • Fig. 12 shows the result of LC and Mass spectrum of ginseng extract (G4)
  • FIG. 13 shows the result of LC and Mass spectrum of ginseng extract (STD).
  • Fig. 14 represents the anticancer activity of the ginseng extract.
  • Non-dried and sliced lkg of Panax ginseng root was placed into crude drug extraction apparatus (2OL/ Kukje-kigong, Korea) and then was heated by steaming at 130°C for 2 hours.
  • the steamed ginseng was dried at 50-60 °C, and pulverized into fine powder with the powder size ranging from 50-200 micrometer to obtain 195g of ginseng powder used as a comparative sample (designated as "STD" hereinafter).
  • distilled water 60OmL of distilled water was placed into crude drug extraction apparatus (2OL/ Kukje- kigong, Korea) and then was heated maintaining the internal temperature ranging from 126°C to 130°C and internal pressure ranging from 2.80 to 3.00 kgf/cm 2 for 2 hours.
  • the processed ginseng was isolated from the water and dried with at 60-70 °C, and pulverized into fine powder with the powder size ranging from 50-200 micrometer to obtain 249g of ginseng powder (yield: 83.0%) used as a sample (designated as "G2-1" hereinafter).
  • Sample preparation [130] 20ml of methanol and 20ml of methylene chloride were added to each 2g of the samples prepared from Comparative Example and Examples and subjected to reflux extraction for 60mins. The solution was cooled, filtrated to remove insoluble material and the supernatant was concentrated to obtain their residue.
  • the weight of each final sample extract was 0.183g (Gl-I), 0.110 (Gl-2), 0.160 (Gl-3), 0.154g (Gl-4), 0.131g (Gl-5), 0.192g (Gl-6), 0.079g (Gl-7), 0.148g (G2-1), 0.070 (G2-2), 0.061g (G2-3), 0.079g (G3), 0.083g (G4) and 0.124g (STD) respectively.
  • the present inventors have been investigated to find optimum extraction condition, especially, the mixture ratio of extracting solvent system by varying the mixture volume ratio of methanol and methylene chloride within the range from 0.60: 1.40 to 1.20:0.80 and finally found that most efficient extraction condition among them is the solvent mixture of methanol and methylene chloride (1 : 1) of which electric conductivity constant is 20.75.
  • test groups were treated with B 16 melanoma cell line to occur cancer and control groups were not treated.
  • the test groups were further classified into two groups, i.e., test group (1) treated with only distilled water and test group (2) treated with equivalent amount of inventive GMM extract at 5 th week and the control groups were also classified into two groups, i.e., control group (1) treated with only distilled water and control group (2) treated with equivalent amount of inventive extract at 5 th week.
  • B 16 melanoma cells were sub-cultured in CO incubator for 1 week and the floated cells diluted RMPI 1640 medium comprising 10% fetal calf serum adjusted to IxIO 6 cells/ml were injected by 0.1ml.
  • the cancer growth rate and survival period was determined by the size of cancer every five days after the injection and the survival period of each group.
  • the cancer growth rate was compared with the weight of cancer and the result was calculated by the following math figure 1.
  • mice occurred cancer in test group (1) while 25% mice in test group (2) at 1 week.
  • 80% and 95% mice occurred cancer in test group (1) respectively while 35% and 42.5% in test group (2) respectively.
  • 100% mice occurred cancer in test group (1) while 52.5% in test group (2).
  • mice in test group (1) and (2) there showed no dead mice in test group (1) and (2) at 12 th day while one mouse was died in test group (1) at 17 day. 85% mice in test group (2) were survived for more than 42 days after the injection of cancer cell and about 50% mice in test group (1) were survived. At 60 day, all the mice in test group (1) were died while 60% mice in test group (2) were survived.
  • the ginseng extract prepared by inventive method in the present invention showed potent anti-cancer activity since the method of the present invention could provide with abundant ginsenoside Rg5 showing potent anticancer activity.
  • Powder preparation was prepared by mixing above components and filling sealed package.
  • Tablet preparation was prepared by mixing above components and entabletting.
  • Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
  • Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2ml ample and sterilizing by conventional injection preparation method.
  • Liquid preparation was prepared by dissolving active component, filling all the components and sterilizing by conventional liquid preparation method. [214]
  • Vitamin mixture optimum amount
  • Vitamin B 0.5mg
  • Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85°C for 1 hour, filtered and then filling all the components in IOOOD ample and sterilizing by conventional health beverage preparation method.
  • the method for preparing processed ginseng according to present invention could provide abundant amount ginsenoside Rg5 showing various pharmacological activities with applying selected specific pressure and temperature into the method and the composition comprising the processed ginseng and the extract thereof can be useful as a medicament or health care food in the prevention or treatment of various diseases, cancer, particularly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de traitement permettant de préparer un produit à base de ginseng puissant pharmacologiquement et son extrait qui peut produire une grande quantité de ginsènoside Rg5 présentant de nombreuses activités pharmacologiques, grâce à l'application d'amplitudes sélectionnées de pression et de températures dans le procédé. La composition comprend, de plus, le ginseng ainsi obtenu et son extrait utilisés en tant que médicament ou aliment de soins dans la prévention ou le traitement de nombreuses maladies, en particulier le cancer.
PCT/KR2006/001324 2005-04-12 2006-04-11 Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5 WO2006109979A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2604064A CA2604064C (fr) 2005-04-12 2006-04-11 Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5
DE112006000924T DE112006000924T5 (de) 2005-04-12 2006-04-11 Neuartiges Verfahren zum Zubereiten von verarbeitetem Ginseng, um eine erhöhte Menge an Ginsenosid RG5 zu erhalten
JP2008506371A JP5185106B2 (ja) 2005-04-12 2006-04-11 ジンセノサイドＲｇ５量を増加させるべく処理された朝鮮人参の新規調製方法
GB0719741A GB2441902B (en) 2005-04-12 2006-04-11 Novel method for preparing ginseng to obtain increased amount of ginsenoside RG5
CN2006800117682A CN101155521B (zh) 2005-04-12 2006-04-11 用于制备加工人参以获得增加的人参皂甙rg5含量的方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2005-0030519 2005-04-12
KR20050030519 2005-04-12
KR10-2006-0032584 2006-04-11
KR1020060032584A KR100777189B1 (ko) 2005-04-12 2006-04-11 진세노시드 Ｒｇ５의 함량을 증대시키기 위한 가공인삼 제조방법

Publications (2)

Publication Number Publication Date
WO2006109979A1 true WO2006109979A1 (fr) 2006-10-19
WO2006109979A9 WO2006109979A9 (fr) 2007-05-10

Family

ID=37087221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/001324 WO2006109979A1 (fr) 2005-04-12 2006-04-11 Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5

Country Status (4)

Country Link
CA (1) CA2604064C (fr)
DE (1) DE112006000924T5 (fr)
GB (1) GB2441902B (fr)
WO (1) WO2006109979A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075866A1 (fr) * 2006-12-18 2008-06-26 Yong Jin Park Composition contenant un extrait transformé de panax quinquefolium l. pour la prévention et le traitement du cancer
JP2011522844A (ja) * 2008-06-12 2011-08-04 チェン スチョン 血糖レベルを低下させる組成物及びその用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004609A (en) * 1996-01-18 1999-12-21 Lee; Sang-Jun Ginseng processing method and processed ginseng prepared by the same
KR100228510B1 (ko) * 1995-11-22 2000-03-15 손경식 진세노사이드Ｒｇ3및/또는Ｒｇ5의제조방법
KR20020052639A (ko) * 2000-12-26 2002-07-04 이상준 인삼 엑기스의 제조방법
KR20030089649A (ko) * 2003-05-28 2003-11-22 주식회사 정문물산 사포닌 고함유 홍삼과 그 제조방법
KR20040004241A (ko) * 2003-11-29 2004-01-13 박명환 인삼의 가공방법
KR20040020693A (ko) * 2002-08-31 2004-03-09 박명환 효능이 증강된 인삼추출물의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
KR20040052639A (ko) * 2004-04-21 2004-06-23 홍명식 냉동 및 냉각장치의 유무선 관리시스템

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100228510B1 (ko) * 1995-11-22 2000-03-15 손경식 진세노사이드Ｒｇ3및/또는Ｒｇ5의제조방법
US6004609A (en) * 1996-01-18 1999-12-21 Lee; Sang-Jun Ginseng processing method and processed ginseng prepared by the same
KR20020052639A (ko) * 2000-12-26 2002-07-04 이상준 인삼 엑기스의 제조방법
KR20040020693A (ko) * 2002-08-31 2004-03-09 박명환 효능이 증강된 인삼추출물의 제조 방법
KR20030089649A (ko) * 2003-05-28 2003-11-22 주식회사 정문물산 사포닌 고함유 홍삼과 그 제조방법
KR20040004241A (ko) * 2003-11-29 2004-01-13 박명환 인삼의 가공방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075866A1 (fr) * 2006-12-18 2008-06-26 Yong Jin Park Composition contenant un extrait transformé de panax quinquefolium l. pour la prévention et le traitement du cancer
JP2011522844A (ja) * 2008-06-12 2011-08-04 チェン スチョン 血糖レベルを低下させる組成物及びその用途

Also Published As

Publication number Publication date
CA2604064A1 (fr) 2006-10-19
GB2441902B (en) 2009-12-30
GB0719741D0 (en) 2007-11-21
GB2441902A (en) 2008-03-19
WO2006109979A9 (fr) 2007-05-10
DE112006000924T5 (de) 2008-03-06
CA2604064C (fr) 2011-08-02

Similar Documents

Publication Publication Date Title
EP1505994B1 (fr) Nouvelle utilisation de l'extrait de ginseng traite et saponine isolee a partir de ce dernier
RU2358749C1 (ru) Способ получения обработанного женьшеня с повышенным количеством гинзенозида rg5
KR101593618B1 (ko) 사포닌의 생체 이용률 증진 조성물
WO2003086438A1 (fr) Extrait de plante du genre panax transforme, procede de preparation de cet extrait et compositions contenant cet extrait
KR102262306B1 (ko) 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물
WO2008147141A1 (fr) Procédé de préparation d'un nouveau ginseng noir-rouge et de l'extrait de celui-ci et composition comprenant l'extrait isolé à partir de celui-ci
WO2007133054A1 (fr) Nouveau procédé de préparation de ginseng noir et composition le compremant
WO2008075866A1 (fr) Composition contenant un extrait transformé de panax quinquefolium l. pour la prévention et le traitement du cancer
CN104666643B (zh) 一种复方雪菊产品及其制备方法和应用
CN107613998A (zh) 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品
KR100542876B1 (ko) 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물
CA2604064C (fr) Nouveau procede pour preparer du ginseng permettant d'obtenir une quantite accrue de ginsenoside rg5
CN101744986B (zh) 人参、麦冬、五味子的单独提取方法及其制剂
KR102099147B1 (ko) 어수리 지하부 및 사상자 혼합 추출물을 유효성분으로 포함하는 비만의 예방, 개선 또는 치료용 조성물
KR20030080296A (ko) 인삼으로부터 분리된 사포닌 분획 및 유도체를 함유하는알러지 질환의 예방 및 치료를 위한 조성물
KR101496155B1 (ko) 진세노사이드 알지5 또는 진세노사이드 알케이1의 함량비율이 증가된 가공 파낙스속 식물 추출물, 그 제조방법, 및 그 가공 파낙스속 식물 추출물을 포함하는 조성물
CN101745016B (zh) 一种"人参,麦冬和五味子"的提取方法及其制剂
CN101745017B (zh) 一种人参、麦冬以及五味子的提取方法及其制剂
KR100456417B1 (ko) 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물
KR100551564B1 (ko) 인삼으로부터 분리된 사포닌 유도체를 함유하는 알레르기질환의 예방 및 치료를 위한 조성물
KR100533505B1 (ko) 인삼으로부터 분리된 사포닌 유도체를 함유하는 알레르기질환의 예방 및 치료를 위한 건강보조식품
CN101745001B (zh) 一种麦冬,人参和五味子的提取方法及其制剂
CN101745000B (zh) 一种人参,麦冬和五味子的提取方法及其制剂
WO2013133677A1 (fr) Composition contenant un mélange réactionnel d'extrait de ginseng rouge et de vinaigre de kaki pour prévenir ou traiter les maladies vasculaires
KR20230104043A (ko) 꽃송이버섯 및 삼칠근을 포함하는 항염증 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680011768.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 7704/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2604064

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 0719741

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20060411

WWE Wipo information: entry into national phase

Ref document number: 0719741.1

Country of ref document: GB

ENP Entry into the national phase

Ref document number: 2008506371

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1120060009249

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2007140693

Country of ref document: RU

RET De translation (de og part 6b)

Ref document number: 112006000924

Country of ref document: DE

Date of ref document: 20080306

Kind code of ref document: P

122 Ep: pct application non-entry in european phase

Ref document number: 06747341

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载